Cholesterol starvation induces differentiation of human leukemia HL-60 cells

Cancer Research

Volumn 67, Issue 7, 2007, Pages 3379-3386

  Sánchez Martín, Carolina C ^a   Dávalos, Alberto ^a   Martín Sánchez, Covadonga ^a   De La Peña, Gema ^a   Fernández Hernando, Carlos ^a   Lasunción, Miguel A ^a,b,c  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 [2 [1 (4 CHLOROCINNAMYL) 4 PIPERAZINYL]ETHYL]BENZOIC ACID; COLECALCIFEROL; DIFFERENTIATION ANTIGEN; GLYCOPROTEIN P 15095; MITOGEN ACTIVATED PROTEIN KINASE; OXIDOREDUCTASE; OXIDOREDUCTASE INHIBITOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RETINOIC ACID; SKF 104976; SQUALENE SYNTHASE; STEROL 14ALPHA DEMETHYLASE; STEROL DELTA 7 REDUCTASE; UNCLASSIFIED DRUG; ZARAGOZIC ACID A; CHOLESTEROL; CYTOCHROME P450; DRUG DERIVATIVE; LANOSTEROL; LANOSTEROL 14 ALPHA-DEMETHYLASE; SK&F 104976;

ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CULTURE MEDIUM; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GRANULOCYTE; HUMAN; HUMAN CELL; LOW FAT DIET; MONOCYTE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; RESPIRATORY BURST; STARVATION; BIOSYNTHESIS; CELL STRAIN HL 60; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CELL DIFFERENTIATION; CHOLESTEROL; CYTOCHROME P-450 ENZYME SYSTEM; HL-60 CELLS; HUMANS; LANOSTEROL; MAP KINASE SIGNALING SYSTEM; OXIDOREDUCTASES;

EID: 34248137573     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4093     Document Type: Article

References (49)

1. Ho YK, Smith RG, Brown MS, Goldstein JL, Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood 1978;52: 1099-114.
2. Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood 1994;84:2689-98.
3. Rudling M, Gafvels M, Parini P, Gahrton G, Angelin B. Lipoprotein receptors in acute myelogenous leukemia: failure to detect increased low-density lipoprotein (LDL) receptor numbers in cell membranes despite increased cellular LDL degradation. Am J Pathol 1998;153:1923-35.
4. Banker DE, Mayer SJ, Li HY, Willman CL, Appelbaum FR, Zager RA. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood 2004;104:1816-24.
5. Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol 2003;23:1055-69.
6. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42.
7. Dimitroulakos J, Yeger H, HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells. Nat Med 1996;2:326-33.
8. Dimitroulakos J, Thai S, Wasfy GH, Hedley DW, Minden MD, Penn LZ. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000;40:167-78.
9. Schmidt F, Groscurth P, Kermer M, Dichgans J, Weller M. Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. Acta Neuropathol (Berl) 2001;101:217-24.
10. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003;101: 3628-34.
11. Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 1999;93:1308-18.
12. Samid D, Shack S, Sherman LT. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 1992;52:1988-92.
13. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998;50:83-93.
14. Denoyelle C, Vasse M, Korner M, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001;22: 1139-48.
15. Boudreau DM, Gardner JS, Malone KE, Heckbert SR, Blough DK, Daling JR. The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer 2004;100:2308-16.
16. Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352: 2184-92.
17. Group HPSC. The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. BMC Med 2005;3:6.
18. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
19. Boudreau DM, Rutter CM, Buist DS. The influence of statin use on breast density. Cancer Epidemiol Biomarkers Prev 2006;15:1026-9.
20. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;23:8606-12.
21. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80.
22. Chang SM, Kuhn JG, Robins HI, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 1999;17:984-90.
23. Schlegel A, Pestell RG, Lisanti MP. Caveolins in cholesterol trafficking and signal transduction: implications for human disease. Front Biosci 2000;5:D929-37.
24. McTaggart SJ. Isoprenylated proteins. Cell Mol Life Sci 2006;63:255-67.
25. 2. FASEB J 1999;13:1359-70.
26. Martínez-Botas J, Ferruelo AJ, Suárez Y, Fernández C, Gómez-Coronado D, Lasunción MA. Dose-dependent effects of lovastatin on cell cycle progression. Distinct requirement of cholesterol and non-sterol mevalonate derivatives. Biochim Biophys Acta 2001;1532:185-94.
27. Fernández C, Martín M, Gómez-Coronado D, Lasunción MA. Effects of distal cholesterol biosynthesis inhibitors on cell proliferation and cell cycle progression. J Lipid Res 2005;46:920-9.
28. Suárez Y, Fernández C, Ledo B, Martín M, Gómez-Coronado D, Lasunción MA. Sterol stringency of proliferation and cell cycle progression in human cells. Biochim Biophys Acta 2005;1734:203-13.
29. Collins SJ. The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. Blood 1987;70:1233-44.
30. Tanaka H, Abe E, Miyaura C, et al. 1α,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem J 1982;204:713-9.
31. Cooper RA, Ip SH, Cassileth PA, Kuo AL. Inhibition of sterol and phospholipid synthesis in HL-60 promyelocytic leukemia cells by inducers of myeloid differentiation. Cancer Res 1981;41:1847-52.
32. Yachnin S, Toub DB, Mannickarottu V. Divergence in cholesterol biosynthetic rates and 3-hydroxy-3-methylglutaryl-CoA reductase activity as a consequence of granulocyte versus monocyte-macrophage differentiation in HL-60 cells. Proc Natl Acad Sci U S A 1984;81: 894-7.
33. 2DCF-DA) or dihydrorhodamine 123 (H2R123). J Immunol Methods 1995;186:275-84.
34. Fernández C, Suárez Y, Ferruelo AJ, Gómez-Coronado D, Lasunción MA. Inhibition of cholesterol biosynthesis by Δ22-unsaturated phytosterols via competitive inhibition of sterol Δ24-reductase in mammalian cells. Biochem J 2002;366:109-19.
35. Rothe G, Valet G. Flow cytometric assays of oxidative burst activity in phagocytes. Methods Enzymol 1994;233: 539-48.
36. Scatena R, Nocca G, Sole PD, et al. Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ 1999;6:781-7.
37. 3 and 12-O-tetradecanoyl phorbol-13-acetate. Leuk Res 2005; 29:1141-51.
38. Bergstrom JD, Kurtz MM, Rew DJ, et al. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc Natl Acad Sci U S A 1993;90:80-4.
39. Miranda MB, McGuire TF, Johnson DE. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines. Leukemia 2002;16: 683-92.
40. Fernández C, Lobo MV, Gómez-Coronado D, Lasunción MA. Cholesterol is essential for mitosis progression and its deficiency induces polyploid cell formation. Exp Cell Res 2004;300:109-20.
41. Ng MM, Chang F, Burgess DR. Movement of membrane domains and requirement of membrane signaling molecules for cytokinesis. Dev Cell 2005;9: 781-90.
42. Drayson MT, Michell RH, Durham J, Brown G. Cell proliferation and CD11b expression are controlled independently during HL60 cell differentiation initiated by 1,25α-dihydroxyvitamin D(3) or all-trans-retinoic acid. Exp Cell Res 2001;266:126-34.
43. Brown G, Hughes PJ, Michell RH. Cell differentiation and proliferation-simultaneous but independent? Exp CeU Res 2003;291:282-8.
44. Jans R, Atanasova G, Jadot M, Poumay Y. Cholesterol depletion up-regulates involucrin expression in epidermal keratinocytes through activation of p38. J Invest Dermatol 2004;123:564-73.
45. Vitols S, Gahrton G, Bjorkholm M, Peterson C. Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet 1985;2:1150-4.
46. Kruth HS, Avigan J, Gamble W, Vaughan M. Effect of cell density on binding and uptake of low density lipoprotein by human fibroblasts. J Cell Biol 1979;83: 588-94.
47. Qui MS, Green SH. PC12 cell neuronal differentiation is associated with prolonged p21ras activity and consequent prolonged ERK activity. Neuron 1992;9: 705-17.
48. Crompton T, Gilmour KC, Owen MJ. The MAP kinase pathway controls differentiation from double-negative to double-positive thymocyte. Cell 1996;86: 243-51.
49. Prusty D, Park BH, Davis KE, Farmer SR. Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor γ (PPARγ) and C/EBPα gene expression during the differentiation of 3T3-1 preadipocytes. J Biol Chem 2002;277: 46226-32.